Whole-genome sequencing with AVITI and NovaSeq X Plus reveals comparable performance with contextual biases.
JSON
Höjer P, Alneberg J, Lundin P, Martin T, Hauenstein J, Fällmar H, Lindell M, Natanaelsson C, Häggqvist S, Ameur A, Nordlund J, Månsson Welinder R
NAR Genom Bioinform 8 (2) lqag053 [2026-06-00; online 2026-05-26]
Element Biosciences' avidity sequencing has emerged as a competing technology to Illumina's short-read sequencing platform. Prior benchmarks of avidity sequencing have not included the latest Illumina NovaSeq X/X Plus instruments with XLEAP chemistry. Here, we have run polymerase chain reaction-free whole-genome sequencing on four human tumor cell lines using both Illumina NovaSeq X Plus and Element AVITI instruments. AVITI showed low duplication rates and reported higher base qualities; the latter contributed to improved mapping confidence and fewer spurious variant candidates. Both platforms were found to be highly comparable when benchmarking variant calling, with AVITI only providing a minor improvement on INDELs at lower coverages. Stratifying by genomic context revealed further differences, where AVITI genome coverage and variant calls were superior in high-GC regions while being inferior in GC homopolymers. Error-rate analysis highlighted further differences between the platforms; in particular, AVITI in some instances displayed an increased error rate on read 2 related to short fragments. AVITI error rate was also found to be more stable downstream of repetitive regions, except for GC homopolymers. We further found that AVITI sequencing was sensitive to G-quadruplex motifs. Overall, despite these identified differences, both platforms performed highly comparable for variant analysis.
NGI Short read [Technology development]
NGI Stockholm (Genomics Applications) [Technology development]
NGI Stockholm (Genomics Production) [Technology development]
National Genomics Infrastructure [Technology development]
PubMed 42206012
DOI 10.1093/nargab/lqag053
Crossref 10.1093/nargab/lqag053
pmc: PMC13202175
pii: lqag053